top of page
Search
Biologics for asthma prevent new-onset diabetes, major adverse cardiovascular events (MACE) as well as other oral corticosteroid (OCS)-related adverse events: Ground-breaking results from SOLAR II
The real-world SOLAR II study shows that biologic initiators had 18% lower risk of developing any oral corticosteroid (OCS)-related...
May 193 min read
Switching or stopping biologic therapy was associated with worse clinical outcomes than continuing the initial therapy: Results from CLEAR
A recently published study in Pragmatic and Observational Research, “Real-world biologic use patterns in severe asthma, 2015–2021: the...
Mar 183 min read
Global disease burden of patients with severe asthma, regardless of biologic accessibility and receipt of biologic treatment: Results from EVEREST
The EVEREST study published in the Journal of Asthma and Allergy, “Disease Burden and Access to Biologic Therapy in Patients with Severe...
Dec 16, 20243 min read
Exploring different composite definitions of responders to biologic treatment for severe asthma (FULL BEAM Response)
The International Severe Asthma Registry  (ISAR) ’s new study, “ Exploring definitions and predictors of response to biologics for severe...
Jul 10, 20243 min read
Exploring definitions and predictors of severe asthma clinical remission post-biologic in adults (FULL BEAM Remission)
We are excited to share groundbreaking findings on remission as a therapeutic target in " Exploring definitions and predictors of severe...
Jul 9, 20242 min read
International research collaboration affirms benefits of biologic therapies across broad severe asthma patient populations worldwide, but also highlights unmet treatment needs: Results from LUMINANT
Singapore, [25 June 2024] – A new analysis of data from the International Severe Asthma Registry (ISAR) has revealed a spectrum of...
Jun 25, 20243 min read
bottom of page